A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2002
12/04/2002	EP1261606A1 Substituted oxazolidinones and their use in the field of blood coagulation
12/04/2002	EP1261605A1 Benzoxazole derivatives as tnf and pde iv inhibitors
12/04/2002	EP1261604A1 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them
12/04/2002	EP1261603A1 Flavone derivatives, preparation method and use as medicines
12/04/2002	EP1261602A1 Imidazol-2-carboxamide derivatives as raf kinase inhibitors
12/04/2002	EP1261601A1 Substituted indoles for modulating nfkb activity
12/04/2002	EP1261600A1 Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2
12/04/2002	EP1261594A1 5,10-dihydroacridines as calcium channel blockers
12/04/2002	EP1261590A1 Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
12/04/2002	EP1261588A1 New imidazole derivatives
12/04/2002	EP1261586A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv, processes for their preparation, and their use
12/04/2002	EP1261585A1 Substituted indole mannich bases
12/04/2002	EP1261583A1 INHIBITORS OF THE ICE/Ced-3 FAMILY OF CYSTEINE PROTEASES
12/04/2002	EP1261379A2 Genetic modification of the lung as a portal for gene delivery
12/04/2002	EP1261372A2 Method of treating cancer with anti-neurotrophin agents
12/04/2002	EP1261361A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1
12/04/2002	EP1261345A1 Herbal supplement for cognitive related impairment due to estrogen loss
12/04/2002	EP1261340A2 Compositions and methods for the treatment of parkinson's disease
12/04/2002	EP1261338A1 Compositions and methods for treatment of epilepsy
12/04/2002	EP1261337A2 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
12/04/2002	EP1261336A2 Il-8 receptor antagonists
12/04/2002	EP1261335A1 Brain, spinal and nerve injury treatment
12/04/2002	EP1261330A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and in lower animals
12/04/2002	EP1261329A2 Il-8 receptor antagonists
12/04/2002	EP1261328A1 Il-8 receptor antagonists
12/04/2002	EP1261327A2 Adenosine receptor modulators
12/04/2002	EP1152763B1 Use of desoxypeganine for the treatment of drug dependence
12/04/2002	EP1100769B1 Aminomethylcarboxylic acid derivatives
12/04/2002	EP1097139B1 Quinoline derivatives
12/04/2002	EP0928291B1 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
12/04/2002	EP0846465B1 Nicorandil against anxiety neurosis
12/04/2002	CN1383449A Stress-relieving perfumes and stress-relieving perfume compsns. contg. same
12/04/2002	CN1383386A Drug delivery device for insertion in vagina, rectum of nasal cavity
12/04/2002	CN1382490A Treatment application of selectivity PDE10 suppressant
12/04/2002	CN1382473A Medicine for treating psychic diseases
12/04/2002	CN1382450A Stem cell medicine for repairing damage of central nerve and its preparing process
12/04/2002	CN1382442A Method for preventing dyskinesia
12/04/2002	CN1382441A Application of gammalon transporter inhibitor in preparing analgesic
12/04/2002	CN1382440A Method and medicine case for treating depression or preventing degeneration of cognitive function
12/04/2002	CN1382436A Slowly releasing analgesic and its preparing process
12/04/2002	CN1095380C Medicine for treating primary menalgia
12/04/2002	CN1095374C Chinese medicine for curing insomnia and neurasthenia
12/04/2002	CA2384907A1 Methods and compositions relating to mek5 and cardiac hypertrophy and dilated cardiomyopathy
12/03/2002	US6489535 Non-mammalian transgenic animal having an adult onset neurodegenerative phenotype
12/03/2002	US6489481 Compounds used for treatment and/or prevention of neuronal apoptosis and/or excitotoxicity related neurological disorders
12/03/2002	US6489477 Nmda nr2b antagonists. accordingly, another aspect of the invention is the treatment of pain, migraine, depression, anxiety, schizophrenia, parkinson's disease, or stroke--maladies that are amenable to amelioration through
12/03/2002	US6489363 For therapy of sleepiness, tiredness, parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, attention deficit hyperactivity disorder, cognitive dysfunction or fatigue, stimulation of appetite
12/03/2002	US6489355 Therapy for alzheimer's disease
12/03/2002	US6489353 Antiinflammatory agents; autoimmune diseases; central nervous system disorders
12/03/2002	US6489352 Antiepileptic agents; nervous system disorders
12/03/2002	US6489350 Methods for treating neuropathic pain using heteroarylmethanesulfonamides
12/03/2002	US6489347 Process
12/03/2002	US6489344 For treatment diabetes in a human or animal subject
12/03/2002	US6489343 Tetrahydropyran derivatives and their use as therapeutic agents
12/03/2002	US6489339 C3A receptor ligands
12/03/2002	US6489334 Method for the crystallization of a tetrahydropyridin derivative and resulting crystalline forms
12/03/2002	US6489333 Heterocyclic compounds containing a guanidine mimic, for inhibition of cell adhesion, treatment of angiogenesis disorders, inflammation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration
12/03/2002	US6489330 Or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of such as famciclovir; prophylactic treatment for kaposi's sarcoma or aids related disease
12/03/2002	US6489328 Heterocyclic compounds useful as inhibitors of tyrosine kinases
12/03/2002	US6489323 Inhibiting no production from l-arginine, as seen in disease states such as arthritis and systemic hypotension associated with septic and/or toxic shock
12/03/2002	US6489322 Benzoxazepines as selective inhibitors of the neuronal isoform of nitric oxide synthase for treatment of neurodegenerative disease
12/03/2002	US6489321 Nonpeptide substituted benzothiazepines as vasopressin antagonists
12/03/2002	US6489313 Improving the memory of a mammal with impaired memory due to aging, wherein said mammal has no diagnosed disease or disorder known to impair memory by administering delta 5-androstene-3 beta-ol-7,17-dione and 3 beta esters thereof
12/03/2002	US6489299 Lysine at position 91 is altered to another amino acid.
12/03/2002	US6489298 Contulakin-G, analogs thereof and uses thereof
12/03/2002	US6488964 Process for manufacturing coated gabapentin or pregabalin particles
12/03/2002	US6488953 Oral transmucosal delivery
12/03/2002	US6488930 Antibody or functional fragment thereof which binds to a mammalian (e.g., human) cc-chemokine receptor 4 (ccr4)
12/03/2002	US6488164 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
12/03/2002	CA2284077C Variants of ciliary neurotrophic factor with enhanced receptor selectivity and method for their selection
12/03/2002	CA2266107C Aralkyl and aralkylidene heterocyclic lactams and imides
12/03/2002	CA2255748C Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
12/03/2002	CA2228249C Pain-alleviating drug composition and method for alleviating pain
12/03/2002	CA2099782C Optically active 5h-pyrrolo[3,4-b] pyrazine, preparation thereof and pharmaceutical compositions contaning same
12/03/2002	CA2074933C Thiazole derivatives as active superoxide radical inhibitors
12/03/2002	CA2065644C Pyrazolopyridine compound and processes for preparation thereof
12/03/2002	CA2042668C Treatment of amyloidosis associated with alzheimer's disease
11/2002
11/30/2002	CA2387699A1 Combination treatment for sleep disorders including sleep apnea
11/28/2002	WO2002095391A1 Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
11/28/2002	WO2002095067A2 INTERFERON α-14 POLYMORPHISM
11/28/2002	WO2002095017A1 Novel mixed lineage kinase (7) (mlk7) polypeptide, polynucleotides encoding the same, and methods of use thereof
11/28/2002	WO2002095012A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
11/28/2002	WO2002095011A2 Inactivation of genes of the mep pathway
11/28/2002	WO2002094997A2 Transcriptional regulation of target genes
11/28/2002	WO2002094990A2 Receptors and membrane-associated proteins
11/28/2002	WO2002094856A2 Gpe analogs and peptidomimetics
11/28/2002	WO2002094834A1 Imidazo [1,5-a] pyrimido [5,4-d] benzazepine derivatives as gaba a receptor modulators
11/28/2002	WO2002094833A1 Novel pyrrole derivatives as pharmaceutical agents
11/28/2002	WO2002094827A1 Fused tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
11/28/2002	WO2002094826A1 Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists
11/28/2002	WO2002094825A1 Novel spiropiperidine derivative
11/28/2002	WO2002094823A1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
11/28/2002	WO2002094821A1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002	WO2002094814A1 3,5-diamino-1,2,4-triazoles as kinase inhibitors
11/28/2002	WO2002094812A1 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002	WO2002094811A1 4-(penyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002	WO2002094810A1 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002	WO2002094808A1 Imidazole-2-carboxamide derivatives as raf kinase inhibitors
11/28/2002	WO2002094802A1 Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives
11/28/2002	WO2002094799A2 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues

1 ... 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 ... 1833